{"id":"NCT02054897","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes","officialTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-03","primaryCompletion":"2015-05-08","completion":"2015-05-08","firstPosted":"2014-02-04","resultsPosted":"2018-01-23","lastUpdate":"2019-06-12"},"enrollment":388,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"semaglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Semaglutide 1.0 mg","type":"EXPERIMENTAL"},{"label":"Semaglutide 0.5 mg","type":"EXPERIMENTAL"},{"label":"Semaglutide placebo 1.0 mg","type":"PLACEBO_COMPARATOR"},{"label":"Semaglutide placebo 0.5 mg","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).","primaryOutcome":{"measure":"Change in HbA1c (Glycosylated Haemoglobin)","timeFrame":"Week 0, week 30","effectByArm":[{"arm":"Semaglutide 0.5 mg","deltaMin":-1.47,"sd":1.02},{"arm":"Semaglutide 1.0 mg","deltaMin":-1.56,"sd":1.26},{"arm":"Placebo","deltaMin":0,"sd":0.9}],"pValues":[{"comp":"OG001 vs OG002","p":"< 0.0001"},{"comp":"OG000 vs OG002","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":86,"countries":["United States","Canada","Italy","Japan","Mexico","Romania","Russia","South Africa","United Kingdom"]},"refs":{"pmids":["30047216","30938762","30865526","28110911","29687620","29748996","29766634","29862621","29907893","30615985","32998732","31903692","31769496"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":128},"commonTop":["Nausea","Diarrhoea","Headache","Nasopharyngitis","Lipase increased"]}}